SCHEMBL29746274

SCHEMBL29746274

COC(=O)c1cccc(-c2ccc(=O)[nH]c2)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 4/20 0.50
▸ SLC6A4 P31645 3/20 0.50
▸ NR4A2 P43354 7/20 0.44
▸ PTPRC P08575 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ ROCK2 O75116 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ SLK Q9H2G2 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ POLB P06746 1/20 0.39
▸ PDK2 Q15119 3/20 0.39
▸ PDK1 Q15118 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29628643 0.83 TSHR (0.46) TSHRMAPTLMNA
SCHEMBL29628231 0.80 SLC6A3 (0.46) SLC6A3SLC6A4NR4A2PTPRCSLC6A2
SCHEMBL19923181 0.79 SLC6A3 (0.59) SLC6A3SLC6A4NR4A2PTPRCSLC6A2
SCHEMBL29109366 0.78 SLC6A3 (0.64) SLC6A3SLC6A4SLC6A2POLBPDK2
SCHEMBL29746180 0.77 SLC6A3 (0.43) SLC6A3SLC6A4NR4A2PTPRCSLC6A2
SCHEMBL29628586 0.76 SLC6A3 (0.45) SLC6A3SLC6A4NR4A2PTPRCSLC6A2
SCHEMBL18190642 0.75 GRIA1 (0.49) SLC6A3SLC6A4PTPRCSLC6A2ROCK2
SCHEMBL28674023 0.72 KMT2A (0.52) SLC6A3SLC6A4NR4A2KMT2A
SCHEMBL18189346 0.72 GRIA1 (0.54) SLC6A3SLC6A4SLC6A2ROCK2CSF1R
SCHEMBL29628499 0.71 SLC6A3 (0.48) SLC6A3SLC6A4NR4A2PTPRCSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3997096-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2024-08-28 — — EP disclosed
US-20220242876-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220242876-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP1A2 SLC6A3 4544/4885SLC6A4 4161/4885NR4A2 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback